New Drug Development for Known and Emerging Viruses

ISBN-13: 9783527343379 / Angielski / Twarda / 2021 / 528 str.

HEL RBSAMEN-SCHAEFF

Spis treści

HIV - Disease overview, targets for therapy and open issues Curing Hepatitis C with Direct-Acting Antiviral Therapy Antiviral Drugs against Influenza Virus Respiratory Syncytial Virus Immunoreactivity, Vaccine development, and Therapeutics Herpes simplex viruses Antiviral strategies against the Human Cytomegalo Virus: Inhibitors of Viral Terminase Antiviral targeting of the complex Epstein Barr virus life cycle Kaposi's Sarcoma-associated Herpesvirus - antiviral treatment Hepatitis B virus: HBV capsid assembly modulators (CAMs) Hepatitis E virus - Current development in antiviral strategies Antiviral Therapy of Adenovirus Infections New Developments in Antiviral Drugs against ssDNA-Viruses: Human Parvovirus Infection Antiviral targets and strategies to treat and prevent human norovirus infections Antiviral strategies against (non-polio) picornaviruses Novel antiviral strategies against emerging arbovirus infections Current Therapies for Biosafety Level 4 Pathogens Antiviral Strategies Against Coronaviruses

O autorze

Helga Rübsamen-Schaeff, PhD, is founding CEO of AiCuris and the chair of AiCuris' Scientific Advisory Board. Before founding AiCuris she served at Bayer as SVP and Head of Infectious Disease Research. Before that time, she was Scientific and Managing Director of the Georg-Speyer-Haus in Frankfurt. A chemist by training, Professor Rübsamen-Schaeff has been professor of biochemistry at the University of Frankfurt since 1988. Her research interests focus on research and development of antiviral drugs, novel resistance-breaking antibiotics, emerging infectious diseases and oncology. Prevymis, a drug against HCMV discovered under her direction has reached the market.Helmut Buschmann, PhD, has over 25 years of international experience in drug discovery research and drug development in the pharmaceutical/biotechnology sectors in different therapeutic areas, from pain research to anti-infectives. Currently, he is Head of Chemistry, Pharmaceutical Development and Patent Affairs at AiCuris and cofounder and co-owner of RD&C Research, Development & Consulting in Vienna.